253 related articles for article (PubMed ID: 23327976)
1. FDA, states discuss pharmacy compounding regulatory framework.
Traynor K
Am J Health Syst Pharm; 2013 Feb; 70(3):180, 182. PubMed ID: 23327976
[No Abstract] [Full Text] [Related]
2. The "Lists": What Do They Mean?
Voliva J
Int J Pharm Compd; 2016; 20(6):477-479. PubMed ID: 28339386
[No Abstract] [Full Text] [Related]
3. 2013 State Compounding Legislation Tracker.
Miller DG
Int J Pharm Compd; 2013; 17(5):375-8. PubMed ID: 24459782
[No Abstract] [Full Text] [Related]
4. U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List).
Int J Pharm Compd; 2016; 20(6):457-458. PubMed ID: 28339383
[No Abstract] [Full Text] [Related]
5. Compounding pharmacies: before and after an inspection.
Kulkarni D; Ricketts S
Int J Pharm Compd; 2013; 17(5):358-62. PubMed ID: 24459779
[TBL] [Abstract][Full Text] [Related]
6. IACP's 2016 Compounders on Capitol Hill Asks.
Int J Pharm Compd; 2016; 20(4):294-296. PubMed ID: 28333674
[No Abstract] [Full Text] [Related]
7. Compounding interest: a tragedy caused by contaminated steroids turned the spotlight on compounding pharmacies.
Hinkley KN
State Legis; 2013 Jun; 39(6):22-3. PubMed ID: 23805443
[No Abstract] [Full Text] [Related]
8. Improving and enforcing compounding pharmacy practices to protect patients.
Pegues DA
Clin Infect Dis; 2006 Oct; 43(7):838-40. PubMed ID: 16941363
[No Abstract] [Full Text] [Related]
9. Federal court strikes down compounding regulations.
Harteker LR
Am J Health Syst Pharm; 2001 Apr; 58(8):638, 640, 643. PubMed ID: 11329752
[No Abstract] [Full Text] [Related]
10. Introduction to Quality Control in a Compounding Pharmacy.
Allen LV
Int J Pharm Compd; 2016; 20(6):481-484. PubMed ID: 28339387
[TBL] [Abstract][Full Text] [Related]
11. Pharmacists want FDA to create new intermediate drug category.
Traynor K
Am J Health Syst Pharm; 2008 Jan; 65(1):10-4. PubMed ID: 18159029
[No Abstract] [Full Text] [Related]
12. President signs compounding law.
Traynor K
Am J Health Syst Pharm; 2014 Jan; 71(1):7. PubMed ID: 24352171
[No Abstract] [Full Text] [Related]
13. Applying Quality by Design Concepts to Pharmacy Compounding.
Timko RJ
Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
[TBL] [Abstract][Full Text] [Related]
14. GMPs vs GCPs: manufacturing and compounding definitions.
Allen LV
Int J Pharm Compd; 2013; 17(5):356. PubMed ID: 24459778
[No Abstract] [Full Text] [Related]
15. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
[TBL] [Abstract][Full Text] [Related]
16. Analytic Methods Used in Quality Control in a Compounding Pharmacy.
Allen LV
Int J Pharm Compd; 2017; 21(1):31-37. PubMed ID: 28346196
[TBL] [Abstract][Full Text] [Related]
17. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
Patsner B
Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
[No Abstract] [Full Text] [Related]
18. Regulation of compounding by the food and drug administration: a tale of 2 circuits.
Williams KG
J Pharm Pract; 2010 Oct; 23(5):502-6. PubMed ID: 21507854
[TBL] [Abstract][Full Text] [Related]
19. Toward Better-Quality Compounded Drugs - An Update from the FDA.
Woodcock J; Dohm J
N Engl J Med; 2017 Dec; 377(26):2509-2512. PubMed ID: 29281577
[No Abstract] [Full Text] [Related]
20. Potential risks of pharmacy compounding.
Gudeman J; Jozwiakowski M; Chollet J; Randell M
Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
